Traditional India Medicine for Woman with PCOD

Epidemiology:

PCOS exhibits marked global heterogeneity: highest burdens in sub-Saharan Africa (13–21%), Middle East (11–16%), and South Asia (including India at 10–22% in urban cohorts like Haryana), with adolescent surges (up to 25% in obese teens aged 10–14) amid rising obesity and sedentary lifestyles. Over three decades (1990–2023), age-standardized prevalence rose 15–20% in Southeast Asia, correlating with urbanization and dietary shifts. (1) (5)

Pathophysiology, Causes, and Risk Factors:

Core etiology involves genetic susceptibility (e.g., variants in DENND1A, LHCGR, FSHR genes; heritability 70–80%), amplified by environmental triggers: ovarian theca cell hyperactivity yielding excess androgens (testosterone ↑20–50%), HPO axis imbalance (LH/FSH ratio 2:1), and peripheral insulin resistance (65–80% prevalence via IRS-1/PI3K defects). Risk amplifiers include central obesity (OR 3.5), familial clustering (20–40% in sisters/daughters), precocious puberty (<11 years; OR 2.8), gestational diabetes exposure, and endocrine disruptors (BPA, phthalates). (3) (6)

Signs and Symptoms:

Rotterdam criteria (2003; 2/3 required):

1. Oligo-/anovulation (cycles >35 days or <8/year; 75–85%)
2. Hyperandrogenism (hirsutism Ferriman-Gallwey score ≥8 in 70%, acne/alopecia, free testosterone ≥2 nmol/L)
3. Polycystic ovaries (≥12 follicles 2–9 mm/ovary or volume ≥10 mL on transvaginal USG).

Metabolic triad: acanthosis nigricans, dyslipidemia (TG ↑30%, HDL ↓20%), non-alcoholic fatty liver.

Long-term: infertility (70–80%), T2DM (40–50% by 40s), CVD (OR 2.7), endometrial cancer (OR 3.5). (3) (6)

Traditional paradigms reframe PCOS: Ayurveda as Artavakshaya/Granthi (Kapha-Vata dominance disrupting Artava dhatu); TCM as phlegm-damp obstructing Ren-Chong meridians; Naturopathy as hormonal-oxidative imbalance amenable to botanicals. (3)

Traditional Medicines:

Prior reviews (2005–2025 systematic compilations) validate 60 herbs/formulations across systems.

Western/European Botanicals:

1. Vitex agnus-castus (Chasteberry): Dopaminergic (binds D2 receptors), ↓ prolactin/LH (20–30%), ↑ progesterone; meta-analyses (11 RCTs, n=552): ovulation 65% vs. 40% placebo, pregnancies 28%. (2) (1)
2. Cinnamon (Cinnamomum zeylanicum): Cinnamaldehyde activates AMPK/IRS-1, ↓ FBS 18%, HOMA-IR 24% (8 RCTs, 12 weeks). (2)
3. Spearmint (Mentha spicata): Anti-androgenic flavonoids ↓ free T 29%, hirsutism ↓15% (2 RCTs, 30 days). (2)
4. Licorice (Glycyrrhiza glabra) + spironolactone: ↓ androgens 36%, superior to monotherapy. (2)

Ayurvedic Formulations:

1. Kanchnar Guggulu: Guggulsterones shrink cysts, ↓ thyroid autoimmunity; combined with Varunadi Kwath: BMI ↓8%, cycles normalized 85% (case series n=50). (3)
2. Kankarakshak Yog (Kanchnar–Ashwagandha–Guduchi–Trikatu): Adaptogenic/anti-IR; 2–3 months: AMH normalized, USG cysts resolved 80%, weight ↓4–6 kg. (3)
3. Shatavari (Asparagus racemosus): Phytoestrogens ↑ FSH, endometrial thickness +25%. (3)

TCM and Others:

1. Cang Fu Dao Tan Tang + Acupuncture: HPO modulation; network meta-analysis (25 RCTs, n=1,842): ovulation OR 3.2 vs. metformin, pregnancy 38%. (4)
2. Berberine (from Coptis): Metformin-equivalent (IR ↓28%), superior lipids. (4)
3. Ginseng (Panax ginseng): Ginsenosides ↑ SOD/GSH-Px, normalize steroidogenesis in PCOS rats. (2)

Table: